(ALVR) Allovir - Ratings and Ratios

Allovir, Inc. (NASDAQ: ALVR) is a clinical-stage biotechnology company specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. These therapies are designed to address severe viral infections and associated diseases. The companys lead product, posoleucel, is an allogeneic VST therapy targeting multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Allovirs pipeline also includes preclinical and clinical candidates such as ALVR106 (targeting respiratory viruses), ALVR109 (SARS-CoV-2/COVID-19), ALVR107 (hepatitis B), and ALVR108. The company, originally founded as ViraCyte, Inc. in 2013, rebranded as Allovir, Inc. in May 2019 and is headquartered in Waltham, Massachusetts.

Allovir focuses on leveraging its proprietary VST technology to create therapies that can be administered off-the-shelf without the need for patient-specific customization. This approach aims to address the limitations of traditional cell therapies, which often require lengthy manufacturing timelines and are limited to a single patient. The companys broad portfolio of virus-specific T cell therapies positions it to potentially treat a wide range of viral-associated diseases, offering a differentiated approach in the field of cell therapy.